2013 - Page 13 of 56 - Blue Horseshoe Stocks

EWSI, CELGZ & Extended Watchlist

E-Waste Systems, Inc. EWSI

–
We talked about EWSI on Friday, at which time it was trading at a low of .043, and have monitored the stock throughout this week. Yesterday, we saw a high of .0519, marking a 21% move off of the bottom. We wanted to see EWSI hold above its 50DMA (.045), and it has thus far managed to do so. Looking forward, we’d like to see the stock continue to hold above that level.

The company had some news out yesterday regarding plans for the opening of the largest e-waste facility in India:

LONDON, UNITED KINGDOM, Oct 08, 2013 (Marketwired via COMTEX) — E-Waste Systems, Inc. (OTCQB: EWSI) (‘EWSI’ or the “Company”), an electronic waste management services, technology and reverse logistics company and the first public pure eWaste company, announced today that it has signed an MOU with Cerebra Integrated Technologies Limited (‘Cerebra’), a publicly traded company listed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). Cerebra, based in Bangalore, India is India’s leading total IT Solutions provider. The agreement calls for the creation, in Bangalore, of the largest E-Waste facility in India, using EWSI’s ePlant1000(TM) technology. The facility is expected to achieve at least 98% recovery of recyclable materials. An investment via a share exchange between the partners is also expected to form part of the relationship.

Celgene Corp. CELGZ
We were watching CELGZ yesterday due to abnormal pre-market activity, for the possibility of quick gains, and that’s just what we got. The stock, after touching a low of 1.39 rumbled upward to as much as 2.70, a 94% intraday gain. This came on roughly 33X the 3mo. average volume.

With that kind of momentum, it appears as if CELGZ’s success could spill over into today’s session, so we’ll want to keep this one high on our watchlists.

Extended Watchlist:

ABIO, INO, AA, GOGO, PROP

ATOS, CTIC, APP & Extended Watchlists

Atossa Genetics, Inc. ATOS

–
We tacked ATOS onto our extended watchlist yesterday morning, noting that the stock was in the midst of a “Huge gap down” and that we were “watching for a potential bounce”. Indeed that was the case, as the stock touched a low of 2.54 before a reversal carried it as high 3.18, a 25% intraday gain. As usual, when we see big gap-downs, we are looking out for quick-strike opportunities that allow us to make a rapid profit and a timely exit.We have uncovered a few other stocks fitting that profile that we will be monitoring for similar activity today:

Tower Group Intl. Ltd. TWGP

CEL-SCI Corp. CVM

Celgene Corp. CELGZ

Cell Therapeutics, Inc. CTIC
Another play from yesterday’s extended watchlist, CTIC opened at its low of day, and rumbled upward for a 23% move, closing at the high of day on nearly 12X its 3mo. average volume. In doing so, it managed to break a previous swing high at 1.80, a level we’d like to see hold as support moving forward.

We prepared the the following video chart on CTIC:

With the kind of momentum CTIC built up over the course of the day yesterday, this is one play that will be near the top of our watchlists in the near future. The catalyst here seems to be an agreement announced yesterday between the company and the FDA as outlined in the press release below.

SEATTLE, Oct. 7, 2013 /PRNewswire via COMTEX/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are <100,000/uL. The SPA is a written agreement between CTI and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application (NDA) submission. The PERSIST-2 trial is the second of two planned Phase 3 clinical trials in patients with myelofibrosis. CTI expects to initiate the PERSIST-2 clinical trial in the fourth quarter of 2013. >>> FULL STORY

American Apparel, Inc. APP

APP is another stock we have tracked for an extended period of time. We have been watching this one to sniff out a bottom for the past few months, and wanted to re-enter it into the conversation today, as that point may be drawing near. A quick peek at the chart below clearly shows just that:

Extended Watchlist:

JCP, AGEN, CBMX, NAVB, TKMR

EWSI, FREE, PLUG, IDRA, DSCO & Extended Watchlist

E-Waste Systems, Inc. EWSI

Following Friday’s newsletter, EWSI opened at its low of day at .043, and would go on to close at its high of day at .05, marking an increase of 16% This comes after we pointed out the stock coming off of a recent bottom, and with a bullish close like we saw on Friday, we are going to be watching this one to make higher lows and higher highs to confirm the current uptrend.

We were clued into re-alerting EWSI on Friday as a result of a good chart setup on both the RSI and the MACD. With no morning gap-up, Friday’s 16% move was purely realized gain.

We have witnessed EWSI run to ten cents in the past, so we know for a fact that it is capable of much larger gains. Indicators seem to point to the current push spanning multiple sessions, leaving it high on our watchlists as we begin a new trading week.

FreeSeas, Inc. FREE
Over the course of a few weeks since we alerted FREE for the first time on 09/10, we have seen FREE go on a mammoth run from .2213 all the way up to .9287, an increase of 320%

Following that peak, the stock has pulled back to find support in the .60-.70 range, and now have it on watch for another possible leg up from these levels. The next key area of resistance from here is going to be the 200DMA at .98.

Plug Power, Inc. PLUG

We first called PLUG on 02/15 as a “potential recovery play” right after we noticed the stock hitting its 52-week lows. What we ended up seeing from PLUG was a recovery, and then some. Over the past several months, the stock not only regained the ground to where it had fallen off a cliff in early February, but the stock has continued its ascent, touching a high of .80 in early September.

As you can see, gains of nearly 600% were possible for anyone who had caught this play at or near its 52-week low on the heels of our initial alert.

Idera Pharmaceuticals, Inc. IDRA
& Discovery Laboratories, Inc. DSCO

Both of these stocks gapped up on Friday after appearing in our extended watchlist, and we still have them on our radars heading into this week.

Each stock traded large volume during Friday’s sessions, so we’re interested to see if they can build up some momentum.

Extended Watchlist:

RNN, ONVO, ONTY, CTIC, TKMR, ATOS(Huge gap down, watching for a potential bounce)

Blue Horseshoe: EWSI & Extended Watchlist

E-Waste Systems, Inc. EWSI

Following our last mention of EWSI, on August 21st, the stock was trading at a low of .0425, and in just six trading sessions, the stock had topped out at .10, racking in gains to the tune of 135%

Following that run, the stock gradually consolidated, as it searched for a bottom throughout the month of September. This morning, we are entering EWSI back into the conversation, as it appears to have found that bottom, and begun to show signs of another uptrend.

The stock breached its 50DMA at .043, and managed to close at that level. The chart is looking extremely ripe, as we’ve pointed out with the annotations below. We definitely want to keep a sharp eye on this stock today, and heading into next week. A return to its previous swing high could mean another triple digit gain from EWSI.

Extended Watchlist:

PTSC, DSCO, IDRA, ASTI, HSOL, STXS

DCTH, ZLCS & Extended Watchlist

Delcath Systems, Inc. DCTH

Following its inclusion in yesterday morning’s extended watchlist, DCTH would go on to have a massively successful day of trading. The stock, after briefly touching a bottom at the .402-mark, went on an absolute tear as it reached a high .66 around lunchtime.

A single-session gain of 64% on the first day we placed DCTH on our watchlist is certainly nothing to sneeze at, and given the circumstances behind the upward surge, that may have only been the beginning.

The company received word from the FDA that its Primary Liver Disease treatment, ChemoSat, had received “orphan drug” designation, a classification which denotes a drug or procedure that is aimed at a disease which affects less than 200,000 people. About 26,000 Americans are diagnosed with Primary Liver Disease each year.

(Thomson Reuters ONE via COMTEX) — New York, NY – October 1, 2013 – Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company orphan drug designation for melphalan in the treatment of patients with hepatocellular carcinoma (HCC, or primary liver cancer). >>>FULL STORY

Side Note:
We rarely see stocks in this price range with an active options chain, but DCTH is an exception. The 12/21 .50 Calls jump out at us at first glance. If the stock were to approach a dollar between now and the expiration date, one could be looking at triple-digit gains.

Zalicus, Inc. ZLCS

Coincidentally, ZLCS, a stock that we’ve been following since the beginning of last month, also received a recent FDA orphan drug designation for its experimental Z160 drug, intended for the treatment of pain related to the Shingles.

Hitting a high of 1.38 yesterday, we finally saw ZLCS fill the gap on the chart that we had been pointing out for some time. Since we’ve been following ZLCS, we’ve seen a low of .78, and yesterday’s high represents a 77% gain off of that bottom. The filling of that gap was a pretty good indicator that it was time to take profits off of the table, so we certainly hope that folks were able to take advantage.

This morning, they also announced a reverse split, the result of which should be the stocks continued listing on the Nasdaq Capital Market, as it should enable shares to remain above the 1.00 minimum bid price required for listing. We would expect shares to come away from this split valued in the $6.00-range, and sure enough, we are seeing trades go off as high as 6.45 pre-market.

Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of Zalicus common stock, effective as of October 3, 2013 at 12:01 a.m. Eastern Time…The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 147.5 million to approximately 24.6 million. >>> FULL STORY

Extended Watchlist:

VICL, CRRS, CIMT, MNTG, RNN, MSTX